Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16582911 | 0.83 | AOC2 (0.54) | SIGMAR1SLC6A4SMN1; SMN2EPHX2NR1H4 | |
| SCHEMBL21654480 | 0.80 | CA2 (0.46) | LMNAKDM4ENR1H4KMT2AALDH1A1 | |
| SCHEMBL46640 | 0.78 | CA2 (0.56) | SIGMAR1SLC6A4LMNASMN1; SMN2KDM4E | |
| SCHEMBL171860 | 0.78 | HPGD (0.59) | LMNASMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL333393 | 0.78 | LMNA (0.49) | LMNAKMT2AALDH1A1POLBHDAC4 | |
| SCHEMBL1972574 | 0.78 | LMNA (0.68) | SIGMAR1LMNASMN1; SMN2KDM4EPOLB | |
| SCHEMBL4475117 | 0.78 | PLK1 (0.59) | PLK1LMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL2398565 | 0.78 | POLB (0.48) | PLK1SIGMAR1SLC6A4LMNASMN1; SMN2 | |
| SCHEMBL10569182 | 0.78 | CA2 (0.56) | LMNAKDM4ENR1H4MAPTKMT2A | |
| SCHEMBL1551331 | 0.77 | CYP4F2 (0.59) | SLC6A4LMNASMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3016950-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-8507453-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507453-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120015896-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION | 2012-01-19 | — | — | US | disclosed |
| US-20120015896-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION | 2012-01-19 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-8053418-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2011-11-08 | — | — | US | disclosed |
| US-8053418-B2 | Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20080300388-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300388-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2008-12-04 | — | — | US | disclosed |
| EP-1849796-A1 | ANTI-PENICILLIN RESISTANT PNEUMOCOCCI AGENT AND NOVEL 16-MEMBERED RING MACROLIDE DERIVATIVE | Microbial Chemistry Research Foundation (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | PLK1 551/4885SIGMAR1 4127/4885SLC6A4 2415/4885 |
| US-20120015896-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | PWWP2B, BRWD1, BAZ1A | PLK1 2590/4885SIGMAR1 4278/4885SLC6A4 4447/4885 |
| US-20080300388-A1 | Anti-Penicillin Resistant Pneumococci Agent and Novel 16-Membered Macrolide Derivative | PWWP2B, BRWD1, BAZ1A | PLK1 2590/4885SIGMAR1 4278/4885SLC6A4 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.